SINUS-24 and SINUS-52

In the SINUS-24 and SINUS-52 trials, there was an 83% reduction in the need for sinus surgery with DUPIXENT vs placebo through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46]).^1,a

DUPIXENT provided a 76% reduction in the need for SCS use and/or sinus surgery through Week 52 vs placebo (HR: 0.24 [95% CI: 0.17, 0.35]).^1,4

^a Individually, need for sinus surgery was not a multiplicity-adjusted endpoint.^1,4

CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyposis; HR, hazard ratio; SCS, systemic corticosteroid.

Learn more about SINUS surgery reduction